About 31 results found for searched term "EGFR-IN-79" (0.112 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M42088 | EGFR-IN-79 | EGFR/HER2 |
| EGFR-IN-79 is an EGFR inhibior with antitumor activity. | ||
| M1850 | WZ4002 | EGFR/HER2 |
| WZ-4002 | ||
| WZ4002 is a novel, selective EGFR kinase inhibitor against EGFR T790M (mutation of the gatekeeper T790 residue) with IC50 of 8 nM. | ||
| M1851 | WZ8040 | EGFR/HER2 |
| WZ8040 is a novel EGFR inhibitor which suppresses the growth of EGFR-T790M-containing cell lines and inhibits EGFR phosphorylation. | ||
| M2424 | AZD9291 (Osimertinib) | EGFR/HER2 |
| Osimertinib; Mereletinib | ||
| Osimertinib (AZD-9291) is an oral, irreversible, and mutant-selective EGFR inhibitor with IC50 of 12.92, 11.44 and 493.8 nM for Exon 19 deletion EGFR, L858R/T790M EGFR, and WT EGFR, respectively. | ||
| M3569 | AST-1306 (TsOH) | EGFR/HER2 |
| AST-6; Allitinib tosylate | ||
| AST-1306 is a novel irreversible inhibitor of EGFR and ErbB2 with IC50 of 0.5 nM and 3 nM, also effective in mutation EGFR T790M/L858R, more potent to ErbB2-overexpressing cells, 3000-fold selective for ErbB family than other kinases, | ||
| M4977 | AZ5104 | FGFR |
| AZ5104, the demethylated metabolite of AZD-9291, is a potent EGFR inhibitor with IC50 of <1 nM, 6 nM, 1 nM, and 25 nM for EGFR (L858R/T790M), EGFR (L858R), EGFR (L861Q), and EGFR (wildtype), respectively. | ||
| M5099 | Osimertinib mesylate (AZD-9291 mesylate) | EGFR/HER2 |
| Mereletinib Mesylate | ||
| Osimertinib mesylate (AZD-9291 mesylate) is an irreversible and mutant selective EGFR inhibitor with IC50s of 12 and 1 nM against EGFRL858R and EGFRL858R/T790M, respectively. | ||
| M5275 | Nazartinib | EGFR/HER2 |
| EGF816, NVS-816 | ||
| Nazartinib (EGF816, NVS-816) is a covalent, irreversible, mutant-selective EGFR inhibitor that has nanomolar inhibitory potency against activating mt (L858R, ex19del) and T790M mt, with up to 60-fold selectivity over wild type (wt) EGFR in vitro. | ||
| M5307 | Afatinib dimaleate | EGFR/HER2 |
| BIBW 2992MA2; BIBW2992; Afatinib | ||
| Afatinib (BIBW2992) Dimaleate irreversibly inhibits EGFR/HER2 including EGFR(wt), EGFR(L858R), EGFR(L858R/T790M) and HER2 with IC50 of 0.5 nM, 0.4 nM, 10 nM and 14 nM, respectively; 100-fold more active against Gefitinib-resistant L858R-T790M EGFR mutant. | ||
| M5346 | WZ3146 | EGFR/HER2 |
| WZ3146 is a mutant-selective irreversible inhibitor of EGFR(L858R) and EGFR(E746_A750) with IC50 of 2 nM and 2 nM; does not inhibit ERBB2 phosphorylation (T798I). | ||
| M6081 | EAI045 | EGFR/HER2 |
| EAI045 is a fourth generation allosteric inhibitor of mutant EGFR, which inhibits EGFR at 10 μM ATP, EGFRL858R, EGFRT790M and EGFRL858R/T790M with IC50 values of 1.9, 0.019, 0.19 and 0.002 μM respectively. | ||
| M43838 | Almonertinib mesylate | EGFR/HER2 |
| HS-10296 mesylate | ||
| Almonertinib mesylate is an orally active, irreversible, third-generation EGFR tyrosine kinase inhibitor with high selectivity for EGFR sensitization and T790M resistance mutations, and also shows strong inhibitory activity against T790M, T790M/L858R, and T790M/Del19, with IC50 of 0.37, 0.29, and 0.21 nM, respectively. The IC50 of T790M/Del19 was 0.37, 0.29 and 0.21 nM, respectively, but the inhibitory effect on wild-type was weaker, with an IC50 of 3.39 nM. It can be used in the research of non-small cell lung cancer. | ||
| M8087 | PF-06459988 | Others |
| PF-06459988 is an orally available irreversible inhibitor of epidermal growth factor receptor (EGFR) mutant (EGFRm) forms including the secondary acquired resistance mutation T790M. | ||
| M9400 | Firmonertinib mesylate | EGFR/HER2 |
| Alflutinib mesylate; AST2818 mesylate | ||
| Firmonertinib (Alflutinib) mesylate is a potent, third generation EGFR inhibitor that targets both EGFR activating mutations and T790M thus leading to tumor growth inhibition. Firmonertinib (AST2818) has the potential for the research of non-small cell lung cancer (NSCLC). | ||
| M9938 | Lazertinib | EGFR/HER2 |
| YH-25448; GNS-1480 | ||
| Lazertinib, also known as YH-25448 and GNS-1480, is an oral active, highly potent, mutant-selective and irreversible EGFR Tyrosine-kinase inhibitors (TKIs) targets both the T790M mutation and activating EGFR mutations while sparing wild type-EGFR. | ||
| M10475 | Lifirafenib (BGB-283) | Raf |
| Beigene-283 | ||
| Lifirafenib (BGB-283) is a novel potent and selective RAF Kinase and EGFR inhibitor with IC50 values of 23, 29 and 495 nM for the recombinant BRAFV600E kinase domain, EGFR and EGFR T790M/L858R mutant. | ||
| M11415 | (Rac)-JBJ-04-125-02 | EGFR/HER2 |
| JBJ-04-125-02 racemate | ||
| (Rac)-JBJ-04-125-02 is a racemate of JBJ-04-125-02, which is a potent, selectively mutated, allosteric and oral active EGFR inhibitor. The IC50 of EGFRL858R/T790M was 0.26 nM. | ||
| M11417 | (S)-Sunvozertinib | EGFR/HER2 |
| (S)-DZD9008 | ||
| (S)-Sunvozertinib ((S)-DZD9008) is the S-enantiomer of Sunvozertinib, EGFR exon 20 NPH and ASV insertion, EGFR L858R/T790M mutation and Her2 exon 20 YVMA insertion (IC50 was 51.2 nM, 51.9 nM, 1 nM and 21.2 nM, respectively). (S)-Sunvozertinib also inhibits BTK. | ||
| M11448 | BLU-945 | EGFR/HER2 |
| ZL-2313 | ||
| Blu-945 is a potent inhibitor of selective epidermal growth factor receptor (EGFR). BLU-945 can effectively inhibit EGFR with L858R and/or exon 19 deletion mutation, T790M mutation and C797S mutation. | ||
| M14131 | AV-412 free base | EGFR/HER2 |
| MP-412 free base | ||
| AV-412 free base (MP-412 free base) is an EGFR inhibitor with IC50s of 0.75, 0.5, 0.79, 2.3, 19 nM for EGFR, EGFRL858R, EGFRT790M, EGFRL858R/T790M and ErbB2, respectively. | ||
| M14132 | Osimertinib dimesylate | EGFR/HER2 |
| AZD-9291 dimesylate; Mereletinib dimesylate | ||
| Osimertinib dimesylate (AZD-9291 dimesylate) is an irreversible and mutant selective EGFR inhibitor with IC50s of 12 and 1 nM against EGFRL858R and EGFRL858R/T790M, respectively. | ||
| M14134 | Rociletinib hydrobromide | EGFR/HER2 |
| CO-1686 hydrobromide; AVL-301 hydrobromide; CNX-419 hydrobromide | ||
| Rociletinib hydrobromide (CO-1686 hydrobromide) is an orally delivered kinase inhibitor that specifically targets the mutant forms of EGFR including T790M, and the Ki values for EGFRL858R/T790M and EGFRWT are 21.5 nM and 303.3 nM, respectively. | ||
| M14135 | Almonertinib | EGFR/HER2 |
| HS-10296 | ||
| Almonertinib (HS-10296) is an orally available, irreversible, third-generation EGFR tyrosine kinase inhibitor with high selectivity for EGFR-sensitizing and T790M resistance mutations. | ||
| M14136 | Almonertinib hydrochloride | EGFR/HER2 |
| HS-10296 hydrochloride | ||
| Almonertinib (HS-10296) hydrochloride is an orally available, irreversible, third-generation EGFR tyrosine kinase inhibitor with high selectivity for EGFR-sensitizing and T790M resistance mutations. | ||
| M27980 | DBPR112 | EGFR/HER2 |
| DBPR112 is an orally active furanopyrimidine-based EGFR inhibitor with IC50s of 15 nM and 48 nM for EGFRWT and EGFRL858R/T790M, respectively. DBPR112 can occupy the ATP-binding site. DBPR112 has significant antitumor efficacy. | ||
| M28940 | Befotertinib | EGFR/HER2 |
| D-0316 | ||
| Befotertinib (D-0316) is the third-generation EGFR tyrosine kinase inhibitor. Befotertinib can be used for the research of EGFR T790M-positive non-small cell lung cancer (NSCLC). | ||
| M29151 | JBJ-04-125-02 | EGFR/HER2 |
| JBJ-04-125-02 is a potent, mutant-selective, allosteric and orally active EGFR inhibitor with an IC50 of 0.26 nM for EGFRL858R/T790M. JBJ-04-125-02 can inhibit cancer cell proliferation and EGFRL858R/T790M/C797S signaling. JBJ-04-125-02 has anti-tumor activities. | ||
| M29464 | JND3229 | EGFR/HER2 |
| JND3229 is a reversible EGFRC797S inhibitor with IC50 values of 5.8, 6.8 and 30.5 nM for EGFRL858R/T790M/C797S, EGFRWT and EGFRL858R/T790M, respectively. JND3229 has good anti-proliferative activity and can effectively inhibit tumour growth in vivo. JND3229 can be used in cancer research, especially in non-small cell carcinoma. | ||
| M29467 | EGFR-IN-7 | EGFR/HER2 |
| TQB3804 | ||
| EGFR-IN-7 is a potent, selective and orally active EGFR kinase inhibitor. EGFR-IN-7 has inhibitory effect for for EGFR (WT) and EGFR (mutant C797S/T790M/L858R) with IC50 values of 7.92 nM and 0.218 nM, respectively. EGFR-IN-7 can be used for the research of various cancers. | ||
| M30826 | EAI001 | EGFR/HER2 |
| EAI001 is a potent, selective mutant epidermal growth factor receptor (EGFR) allosteric inhibitor with an IC50 value of 24 nM for EGFRL858R/T790M. EAI001 can be used for research of cancer. | ||
| M40638 | BBT-176 | EGFR/HER2 |
| BBT-176 is a novel, EGFR tyrosine kinase inhibitor (TKI) targeting the C797S mutation for studies related to non-small cell lung cancer (NSCLC). | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
